Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China Biotech Services HoldingsHKSE:08037 31 Cyclically Adjusted PB Ratio is 1.60 as of Aug. 17, 2026, which is 162% above its 10-year median of 0.61. GuruFocus rates HKSE:08037 with a GF Score™ of 31/100 and a GF Value™ of HK$0.26 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 130 Medical Diagnostics & Research companies, China Biotech Services Holdings ranks better than 53.08% on this metric.
The historical rank and industry rank for China Biotech Services Holdings's Cyclically Adjusted PB Ratio or its related term are showing as below:
HKSE:08037'
s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.02 Med: 0.61 Max: 2.9
Current: 1.61
During the past 13 years, China Biotech Services Holdings's highest Cyclically Adjusted PB Ratio was 2.90. The lowest was 0.02. And the median was 0.61.
HKSE:08037's Cyclically Adjusted PB Ratio is ranked better than 53.08% of 130
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.815
vs HKSE:08037: 1.61
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
China Biotech Services Holdings's adjusted book value per share data of for the fiscal year that ended in Dec25 was HK$0.198. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is HK$0.39 for the trailing ten years ended in Dec25.
Shiller PE for Stocks: The True Measure of Stock Valuation
China Biotech Services Holdings (HKSE:08037) Cyclically Adjusted PB Ratio Explanation
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
China Biotech Services Holdings Cyclically Adjusted PB Ratio Related Terms
China Biotech Services Holdings Cyclically Adjusted PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Biotech Services Holdings Cyclically Adjusted PB Ratio Chart
HKSE:08037 vs TMO, DHR, IDXX: Cyclically Adjusted PB Ratio Comparison
For the Diagnostics & Research subindustry, China Biotech Services Holdings's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Biotech Services Holdings Cyclically Adjusted PB Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, China Biotech Services Holdings's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where China Biotech Services Holdings's Cyclically Adjusted PB Ratio falls into.
China Biotech Services Holdings Cyclically Adjusted PB Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PB Ratio of 1.60 mean?
China Biotech Services Holdings (HKSE:08037) has a Cyclically Adjusted PB Ratio of 1.60 as of Aug. 17, 2026. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on China Biotech Services Holdings and its competitors. This is 162% above median its historical median of 0.61. Over the past decade, China Biotech Services Holdings' Cyclically Adjusted PB Ratio has ranged from 0.02 to 2.90. According to the industry distribution chart, China Biotech Services Holdings ranks #61 out of 130 companies in the Medical Diagnostics & Research industry, placing it in the top 46.9%.
Is China Biotech Services Holdings' Cyclically Adjusted PB Ratio too high?
China Biotech Services Holdings' current Cyclically Adjusted PB Ratio of 1.60 is 162% above median its 10-year median of 0.61. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 2.90. The Medical Diagnostics & Research industry median Cyclically Adjusted PB Ratio is 1.82. China Biotech Services Holdings' value of 1.60 is 11.8% below this industry median. Based on the distribution chart, China Biotech Services Holdings ranks #61 out of 130 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, China Biotech Services Holdings has a GF Score™ of 31/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does China Biotech Services Holdings' Cyclically Adjusted PB Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, China Biotech Services Holdings ranks #61 out of 130 companies for Cyclically Adjusted PB Ratio. This puts China Biotech Services Holdings in the upper half of its industry. The industry median Cyclically Adjusted PB Ratio is 1.82. China Biotech Services Holdings' value of 1.60 is 11.8% below this benchmark. Historically, China Biotech Services Holdings' own Cyclically Adjusted PB Ratio has ranged from 0.02 to 2.90 over the past decade. While the company's 10-year median is 0.61 vs. the industry median of 1.82, China Biotech Services Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PB Ratio for a Medical Diagnostics & Research company?
The median Cyclically Adjusted PB Ratio among Medical Diagnostics & Research companies is 1.82, based on 130 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Biotech Services Holdings's current Cyclically Adjusted PB Ratio of 1.60 is 11.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PB Ratio mean?
A high Cyclically Adjusted PB Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on China Biotech Services Holdings and its competitors. For the Medical Diagnostics & Research industry, the median Cyclically Adjusted PB Ratio is 1.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Biotech Services Holdings's current Cyclically Adjusted PB Ratio is 1.60, which is 162% above median its own 10-year median of 0.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Biotech Services Holdings stock overvalued right now?
Based on GuruFocus' analysis, China Biotech Services Holdings (HKSE:08037) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.26, compared to a current price of HK$0.63 — trading 140.4% above its estimated fair value. The current Cyclically Adjusted PB Ratio is 1.60, which is 162% above median its 10-year median of 0.61 and 11.8% below the Medical Diagnostics & Research industry median of 1.82. China Biotech Services Holdings' overall GF Score™ is 31/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PB Ratio calculated?
Cyclically Adjusted PB Ratio is calculated from a company's financial statements. For China Biotech Services Holdings (HKSE:08037), the current Cyclically Adjusted PB Ratio is 1.60 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Biotech Services Holdings (HKSE:08037) Overvalued in 2026?
Based on GuruFocus' analysis, China Biotech Services Holdings stock appears to be overvalued.
The current stock price of HK$0.63 is trading 140.4% above its estimated GF Value™ of HK$0.26.
GuruFocus considers China Biotech Services Holdings to be Significantly Overvalued.
Key valuation signals for HKSE:08037:
Cyclically Adjusted PB Ratio: 1.60 (162% above median its 10-year median of 0.61)
GF Value™: HK$0.26 vs. price of HK$0.63 (140.4% above fair value)
Industry Position: 11.8% below the Medical Diagnostics & Research median (#61 of 130)
No single metric tells the full story. See the HKSE:08037 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Biotech Services Holdings Ltd is an investment holding company. It operates through five segments: Pharmaceutical Products, Medical and Health-Related Services, Immunotherapy, Insurance brokerage, BNCT, and Others. It derives prime revenue from the Medical & health-related services segment, which involves the provision of medical laboratory testing & health check services. The group has a business presence in Hong Kong & the PRC, of which key revenue is generated from Hong Kong. Immunotherapy-provision of tumor immune cell therapy & health management services. Pharmaceutical products-sale & distribution of health-related & pharmaceutical products. Insurance brokerage services. BNCT-provision of boron neutron capture therapy treatment services, & Others-provision of logistic services.
31GF Score
Get the complete analysis for HKSE:08037
Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:08037 has been successfully added to your 
